Apnimed (NASDAQ:APMD) Research Coverage Started at Lifesci Capital

Lifesci Capital initiated coverage on shares of Apnimed (NASDAQ:APMD) in a research report released on Tuesday,Benzinga reports. The firm issued an outperform rating and a $50.00 price target on the stock.

Several other brokerages have also issued reports on APMD. Evercore began coverage on shares of Apnimed in a research note on Tuesday. They issued an “outperform” rating on the stock. Wall Street Zen upgraded Apnimed to a “hold” rating in a report on Saturday, August 8th. Cantor Fitzgerald began coverage on Apnimed in a report on Tuesday. They set an “overweight” rating and a $60.00 target price on the stock. Finally, Bank of America assumed coverage on shares of Apnimed in a research note on Tuesday. They issued a “buy” rating and a $41.00 price target for the company. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $50.33.

Apnimed Stock Down 2.9%

Shares of APMD stock opened at $28.72 on Tuesday. Apnimed has a 12 month low of $16.12 and a 12 month high of $35.29.

Insider Buying and Selling

In related news, major shareholder Morningside Venture Investment acquired 312,500 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was purchased at an average cost of $16.00 per share, with a total value of $5,000,000.00. Following the acquisition, the insider directly owned 7,152,713 shares of the company’s stock, valued at approximately $114,443,408. The trade was a 4.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Apnimed Company Profile

Apnimed Inc is a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies which address the neurobiology of sleep-related breathing diseases. Apnimed Inc is based in CAMBRIDGE, Mass.